Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

TSLP Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (1) Fc Receptor (FcR) (1) Interleukin Related (15) STAT (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (16) Metabolic Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99366A

*Tezepelumab (anti-TSLP)* AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)	Interleukin Related	Inflammation/Immunology
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to *TSLP*, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .

HY-P990774

Verekitug ASP-7266; TRAB-1; UPB-101	Interleukin Related	Inflammation/Immunology
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting *TSLP*-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .

HY-P991471

GB-0895	Interleukin Related	Inflammation/Immunology
GB-0895 is a human monoclonal antibody (mAb) targeting *TSLP*. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991162

Tilrekimig PF-07275315	Interleukin Related	Inflammation/Immunology
Tilrekimig (PF-07275315) is a monoclonal antibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .

HY-P990906

Bosakitug BSI-045B; TQC2731	Interleukin Related	Inflammation/Immunology
Bosakitug (BSI-045B) is an *TSLP*-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Bosakitug can be used in the research of inflammatory diseases such as moderate to severe atopic dermatitis .

HY-P990933

Ocankitug CM-326	Interleukin Related	Inflammation/Immunology
Ocankitug (CM-326) is a humanized IgG1κ antibody targeting thymic stromal lymphopoietin (TSLP). It can be used for research on type 2 inflammatory respiratory diseases, including moderate to severe asthma, chronic sinusitis with nasal polyps, etc.

HY-P990023

Bempikibart ADX-914	Interleukin Related	Metabolic Disease Inflammation/Immunology
Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and thymic stromal lymphopoietin (TSLP). Bempikibart can be used for the study of atopic dermatitis and alopecia areata .

HY-P99872

Ecleralimab CSJ-117; NVP-CSJ117	Interleukin Related	Inflammation/Immunology
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .

HY-P990150

Anti-Mouse TSLP Antibody (28F12)	Interleukin Related	Inflammation/Immunology
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse *TSLP* IgG2a monoclonal antibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .

HY-P991717

Sunakiment AZD-8630	Interleukin Related	Inflammation/Immunology Cancer
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .

HY-P990535

**Anti-TSLP Antibody**	Interleukin Related	Inflammation/Immunology
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting *TSLP. The Anti-TSLP* Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991720

Tepilukimig	Interleukin Related	Inflammation/Immunology
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and *TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP* to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .

HY-P991684

Felcorekibart	Interleukin Related	Inflammation/Immunology
Felcorekibart is a humanized IgG1κ antibody targeting *TSLP*. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992447

QX008N	Interleukin Related	Inflammation/Immunology
QX008N is a humanized IgG1 monoclonal antibody and also a *TSLP* inhibitor with a K_D value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of *TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies*. QX008N is applicable to relevant research on asthma .

HY-P992474

TAVO101	Interleukin Related STAT CCR Fc Receptor (FcR)	Inflammation/Immunology
TAVO101 is a humanized anti-TSLP antibody with an EC₅₀ of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99366A

*Tezepelumab (anti-TSLP)* AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)	Interleukin Related	Inflammation/Immunology
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to *TSLP*, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .

HY-P990774

Verekitug ASP-7266; TRAB-1; UPB-101	Interleukin Related	Inflammation/Immunology
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting *TSLP*-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .

HY-P991471

GB-0895	Interleukin Related	Inflammation/Immunology
GB-0895 is a human monoclonal antibody (mAb) targeting *TSLP*. GB-0895 can be used in Asthma research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991162

Tilrekimig PF-07275315	Interleukin Related	Inflammation/Immunology
Tilrekimig (PF-07275315) is a monoclonal antibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .

HY-P990906

Bosakitug BSI-045B; TQC2731	Interleukin Related	Inflammation/Immunology
Bosakitug (BSI-045B) is an *TSLP*-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Bosakitug can be used in the research of inflammatory diseases such as moderate to severe atopic dermatitis .

HY-P990933

Ocankitug CM-326	Interleukin Related	Inflammation/Immunology
Ocankitug (CM-326) is a humanized IgG1κ antibody targeting thymic stromal lymphopoietin (TSLP). It can be used for research on type 2 inflammatory respiratory diseases, including moderate to severe asthma, chronic sinusitis with nasal polyps, etc.

HY-P990023

Bempikibart ADX-914	Interleukin Related	Metabolic Disease Inflammation/Immunology
Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and thymic stromal lymphopoietin (TSLP). Bempikibart can be used for the study of atopic dermatitis and alopecia areata .

HY-P99872

Ecleralimab CSJ-117; NVP-CSJ117	Interleukin Related	Inflammation/Immunology
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .

HY-P990150

Anti-Mouse TSLP Antibody (28F12)	Interleukin Related	Inflammation/Immunology
Anti-Mouse TSLP Antibody (28F12) is an anti-mouse *TSLP* IgG2a monoclonal antibody. Anti-Mouse TSLP Antibody (28F12) weakens skin inflammation and allergic reactions by reducing Treg cells and lymph node cells. Anti-Mouse TSLP Antibody (28F12) can be used for research on allergic conditions .

HY-P991717

Sunakiment AZD-8630	Interleukin Related	Inflammation/Immunology Cancer
Sunakiment is a humanized IgG1λ monoclonal antibody inhibitor targeting Thymic stromal lymphopoietin (TSLP). Sunakiment can be used for inflammatory and immune system disorders like ulcerative colitis, rheumatoid arthritis and allergy and cancers research .

HY-P990535

**Anti-TSLP Antibody**	Interleukin Related	Inflammation/Immunology
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting *TSLP. The Anti-TSLP* Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991720

Tepilukimig	Interleukin Related	Inflammation/Immunology
Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and *TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP* to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .

HY-P991684

Felcorekibart	Interleukin Related	Inflammation/Immunology
Felcorekibart is a humanized IgG1κ antibody targeting *TSLP*. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992447

QX008N	Interleukin Related	Inflammation/Immunology
QX008N is a humanized IgG1 monoclonal antibody and also a *TSLP* inhibitor with a K_D value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of *TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies*. QX008N is applicable to relevant research on asthma .

HY-P992359

GSK5784283 SHR-1905	Inhibitory Antibodies	Inflammation/Immunology
GSK5784283 (SHR-1905) is a bispecific epitope antibody against *TSLP* that can be used in research related to asthma. GSK5784283 effectively reduces the levels of eosinophils, FeNO, TARC and eotaxin-3. GSK5784283 regulates FEV1 (forced expiratory volume in 1 second) .

HY-P992474

TAVO101	Interleukin Related STAT CCR Fc Receptor (FcR)	Inflammation/Immunology
TAVO101 is a humanized anti-TSLP antibody with an EC₅₀ of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.